Aldeyra
Yahoo Finance • 8 days ago
Vertex Posts Positive Phase II Data on Kidney Disease Drug
Vertex Pharmaceuticals VRTX announced positive data from the phase IIb AMPLIFIED study, which evaluated its investigational drug, inaxaplin, for the treatment of patients with APOL1-mediated kidney disease ("AMKD") and modest proteinuria a... Full story
Yahoo Finance • 8 days ago
AstraZeneca's Trixeo Secures Approval for Asthma in the EU
AstraZeneca AZN announced that the European Commission has approved its respiratory drug, Trixeo Aerosphere, for a new indication. The drug is approved in the European Union (EU) as a maintenance treatment for previously treated asthma pa... Full story
Yahoo Finance • 9 days ago
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis
AbbVie ABBV announced that the European Commission ("EC") has approved its blockbuster immunology drug, Rinvoq (upadacitinib), for a new indication. The drug is approved in the European Union for the treatment of active polyarticular juven... Full story
Yahoo Finance • 9 days ago
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study
Novo NVO announced top-line results from two phase III studies evaluating once-weekly CagriSema, its investigational fixed-dose combination of cagrilintide and semaglutide, in obesity and type II diabetes (T2D). In the REIMAGINE 5 study, C... Full story
Yahoo Finance • 10 days ago
AZN's Klygefa Gets CHMP Nod for Generalised Myasthenia Gravis in EU
AstraZeneca AZN announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending the approval of its rare-disease drug, Klygefa (gefurulimab), as an add-on... Full story
Yahoo Finance • 10 days ago
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EU
Novo NVO announced that its once-weekly growth hormone therapy Sogroya (somapacitan) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating children with idiopath... Full story
Yahoo Finance • 13 days ago
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union
Novo NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending the approval of denecimig (Mim8) for the treatment of hemophilia A, with or witho... Full story
Yahoo Finance • 14 days ago
Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery
Novo NVO is expanding its artificial intelligence (AI) capabilities through a new collaboration with Anthropic to accelerate drug discovery and development of new medicines. Under the agreement, Novo will use Anthropic's models and Claude... Full story
Yahoo Finance • 20 days ago
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
AbbVie ABBV announced positive top-line data from the phase III LUNA study, which evaluated atogepant, an oral calcitonin gene-related peptide receptor antagonist, for preventive treatment of menstrual migraine in adult women. Menstrual mi... Full story
Yahoo Finance • 21 days ago
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
Bayer BAYRY announced that the FDA has granted approval to sevabertinib through an accelerated pathway for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have... Full story
Yahoo Finance • 29 days ago
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
AstraZeneca AZN announced positive data from the phase III SANOVO study evaluating Tagrisso (osimertinib) plus Orpathys (savolitinib) in treatment-naïve patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC) w... Full story
Yahoo Finance • last month
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down
BioNTech BNTX announced that it has discontinued the phase II BNT122-01 study evaluating autogene cevumeran for the treatment of patients with high-risk stage II or stage III colorectal cancer ("CRC") whose tumors had been surgically remov... Full story
Yahoo Finance • last month
LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes
The FDA has approved Eli Lilly's LLY Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type II diabetes (T2D). The new indication includes patients with T2D who are at high risk for major adverse cardiovascular events (M... Full story
Yahoo Finance • 4 months ago
Pre-Market Movers: TNGX, WOK, GOCO Set The Path
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, hinting at possible breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. Price swings ahead of t... Full story
Yahoo Finance • 4 months ago
ALDEYRA DEADLINE FRIDAY MAY 29th: Bragar Eagel & Squire, P.C. Urgently Reminds Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aldeyra (ALDX) To Contact Him Directly To Discuss Their Options If you purchased or acquired Aldeyra securities between November 3,... Full story
Yahoo Finance • 4 months ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Daniell... Full story
Yahoo Finance • 4 months ago
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, May 25, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (“Aldeyra” or “the Company”) (NASDAQ: ALDX)... Full story
Yahoo Finance • 4 months ago
Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action Against Aldeyra Therapeutics, Inc.
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between Novemb... Full story
Yahoo Finance • 4 months ago
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) and c... Full story
Yahoo Finance • 4 months ago
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between November 3, 2023 and March 16, 2026, both dates inc... Full story